Alphatec Holdings, Inc.
Alphatec is a medical technology company headquartered in Carlsbad, California, focused on designing and developing technology for surgical treatment of spine disorders. It sells a broad portfolio of spinal implants, fixation systems, surgical access instruments, patient positioners and biologics, along with imaging, surgical-planning software, neuromonitoring, and navigation and robotics technologies. Its procedural offerings include the Prone TransPsoas, Lateral TransPsoas and Midline ALIF approaches, as well as solutions for cervical, deformity and other spine procedures. Alphatec markets and sells its products through exclusive independent sales agents and direct sales representatives. It generally invoices hospitals for products used in surgery and pays sales commissions based on payments received. Its EOS sales team focuses on hospital administrators. The company also provides surgeon training and education, including programs at its Carlsbad headquarters. It relies on third-party suppliers to manufacture its implants and instruments.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ATEC in the last 30 days.
See all $ATEC insider activity →Alphatec Holdings Inc. (ATEC) reported a Q3 loss of $5.5 million, or 3 cents per share, with adjusted earnings of 9 cents per share. Revenue was $221.2 million, missing estimates of $224.3 million. The company expects full-year revenue of $862 million. ATEC shares have fallen 46% YTD and 31% over the past year.
Alphatec Holdings, Inc. (ATEC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ATEC Reports Third Quarter Financial Results Total revenue of $221 million, up 13% year-over-year Surgical revenue of $202 million increased 14% Case volumes grew 20% and net new surgeon users increased 25% CARLSBAD, Calif., October 29, 2026 – Alphatec Holdings, Inc.
Alphatec Holdings (ATEC) will report Q3 2026 results on Oct 29 after market close. A live webcast at 4:30 p.m. ET will follow, with a Q&A session for registered analysts. A replay will be available for 12 months. ATEC focuses on innovative spine surgery solutions.
Over the past 7 days, AlphAI's AI scored 10 news stories mentioning ATEC (Alphatec Holdings, Inc.). Coverage has skewed bearish: 0 bullish, 2 neutral, and 8 bearish.
Recent ATEC coverage spans earnings, financial news and insider activity.
Earnings miss plus explicit full-year revenue outlook likely keeps downside pressure on valuation and raises scrutiny on demand and margins.
Quarterly revenue of $221M rose 13% YoY, but GAAP net loss of $5M and a shortfall versus internal expectations may pressure the stock.
Earnings release may cause short-term volatility as investors react to the upcoming financial results.
The earnings beat and strong revenue drive a sharp price rally, suggesting further upside if guidance holds.
The headline catalyst is a same-day insider buy tied to improving operating momentum, which can support near-term sentiment and momentum trading.
AlphAI scores every news story that mentions ATEC with an AI model for sentiment and relevance, and aggregates insider trades from Alphatec Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Alphatec Holdings Inc. (ATEC) reported a Q3 loss of $5.5 million, or 3 cents per share, with adjusted earnings of 9 cents per share. Revenue was $221.2 million, missing estimates of $224.3 million. The company expects full-year revenue of $862 million. ATEC shares have fallen 46% YTD and 31% over the past year.
2 min readAlphatec Holdings, Inc. (ATEC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ATEC Reports Third Quarter Financial Results Total revenue of $221 million, up 13% year-over-year Surgical revenue of $202 million increased 14% Case volumes grew 20% and net new surgeon users increased 25% CARLSBAD, Calif., October 29, 2026 – Alphatec Holdings, Inc.
2 min readAlphatec Holdings (ATEC) will report Q3 2026 results on Oct 29 after market close. A live webcast at 4:30 p.m. ET will follow, with a Q&A session for registered analysts. A replay will be available for 12 months. ATEC focuses on innovative spine surgery solutions.
1 min readAlphatec (ATEC) shares rose 19.7% to $10.58 on strong Q2 2026 results, with EPS of $0.07 and revenue of $213.5M. The company expects full-year revenue of $882M. Analysts forecast Q3 EPS of $0.11 and revenue of $224.28M. ClearPoint Neuro (CLPT) also mentioned, up 1.8% to $13.72.
2 min readAlphatec Holdings (ATEC) surged 19.67% after its CEO bought $1 million in stock. The medtech company focuses on spinal surgery tech and has strong growth metrics, with Wall Street analysts averaging a $17 price target. Other stocks mentioned include HPE, NTA, INSP, CVI, and INTC, with notable gains in September.
6 min readAlphatec Holdings (ATEC) stock rose 19.1% after CEO Patrick Miles bought 115,000 shares for $1.01M at $8.81 each. The company reported Q2 revenue of $213.5M, up 15% YoY, and reaffirmed FY2026 guidance of $882M. The move coincided with a broader market rebound, with the S&P 500 and Nasdaq gaining 1.0% and 1.1% respectively.
2 min readMiles Patrick (CEO) purchased 115,000 shares of Alphatec Holdings, Inc. (ATEC) at $8.81 ($1.01M total) on 2026-09-10.
1 min readAlphatec Holdings (NASDAQ:ATEC) reported Q2 2026 revenue of $214 million, up 15% year over year, with surgical revenue at $196 million, up 17%. Adjusted EBITDA rose to $36 million, up 53%, with GAAP gross margin 72.2%. Management reaffirmed full-year revenue guidance near $882 million and raised adjusted EBITDA guidance to about $140 million.
6 min readAlphatec Holdings (ATEC) reported Q2 results with a reduced net loss of $25.78 million year over year and reaffirmed 2026 revenue guidance of about $882 million, according to the company. It also filed an $8.12 million shelf registration for 800,000 common shares tied to an ESOP. The update supported a 5.9% stock rise.
4 min readAlphatec Holdings (ATEC) reported Q2 2026 revenue of $214 million, up 15% year over year, with surgical revenue at $196 million, up 17%. Adjusted EBITDA rose 53% to $36 million, and GAAP gross margin was 72.2%. Management reaffirmed full-year revenue guidance near $882 million and raised adjusted EBITDA guidance to about $140 million.
7 min read
